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Prognosis of patients with metastatic melanoma is poor (Ketcham
and Balch, 1985; Tafra et al, 1995), with an annual risk of death of
about 20% during the first 3 years (Slingluff et al, 1992). The
second most common site for metastatic spread is the lung (Balch
and Milton, 1985), and the annual probability of developing
pulmonary metastases increases progressively from 10% at 5 years
to 17% at 15 years. Overall long-term survival for such patients is
poor, with only 4% of patients alive at 4 years (Harpole et al,
1992).
As effective chemotherapy for metastatic melanoma is not
available, surgery can represent the only prospect of cure for
highly selected patients (Wong et al, 1993; Karakousis et al, 1994).
However only 10–12% of cases are suitable for surgery with cura-
tive intent (Cahan, 1973; Mountain et al, 1984; Thayer and
Overholt, 1985; Pogrebniak et al, 1988; Gorenstein et al, 1991).
Moreover, surgical results are still controversial as the majority of
published studies are based on a small number of cases with rela-
tively short follow-up.
Two large series have already confirmed the prognostic value of
factors such as radicality, number of resected metastases and
disease-free interval (DFI) after pulmonary metastasectomy
(Harpole et al, 1992; Tafra et al, 1995) but it remains unclear how
these data can be used for preoperative patient selection.
The purpose of this study is to evaluate the long-term results of
surgery in melanoma pulmonary metastases from the International
Registry of Lung Metastases (IRLM) data, with the aim of
defining the subset of patients that really benefit from surgery.
PATIENTS AND METHODS
Of the 5206 patients recorded in the International Registry of Lung
Metastases in the period 1945–1995, 328 (6.3%) had operations
for pulmonary stage IV melanoma. The aims of the Registry,
methodology of data collection and analysis have been published
previously (Pastorino et al, 1997). In summary, all patients who
had undergone resection of pulmonary metastases with curative
intent were eligible for inclusion if their primary tumour, as well as
metastases in other organs, had been effectively treated. Eighteen
major centres from Europe, the USA and Canada took part in the
project.
Data analysis
Survival time was calculated from first metastasectomy to the last
date of follow-up, by means of the Kaplan–Meier estimate. Mean
follow-up of patients alive was 42 months.
The impact on survival of the following variables was tested:
age, sex, radicality of metastasectomy, time to pulmonary metas-
tases (time from surgery of primary melanoma to diagnosis of
pulmonary metastases, TPM), number of pathologically confirmed
metastases, resection volume, nodal involvement, delay of surgery
from diagnosis of metastases to metastasectomy, chemotherapy,
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Differences were tested by the log-rank test. A Cox regression
model evaluated all variables with statistically significant impact
on survival.
Finally, the prognostic grouping proposed by the International
Registry of Lung Metastases in 1997 was tested to assess its value
in patients with metastatic melanoma.
Patient details
One hundred and eighty-one patients were male (55.2%) and 147
were female (44.8%) with a mean age of 49 years (range 14–78).
Sixty-eight patients (20.7%) had adjuvant therapy in addition to
surgical resection of the primary melanoma (chemotherapy with or
without radiotherapy in 59 patients, radiotherapy in nine patients).
Before metastasectomy, 73 patients (22.2%) required further treat-
ment for recurrence of melanoma at the primary site (51 for single
recurrence and 22 for multiple recurrence).
Mean TPM was 53 months for the whole series, 54 months for
radical metastasectomies and 42 months for incomplete resections.
Fifteen patients had one or more lung metastases synchronous
with primary tumour, 40 patients had a TPM < 12 months, 102 had
a TPM of 12–35 months, 163 patients (49.7%) had a TPM > 36
months (Table 1). Information about TPM was not available for
eight patients (2.4%).
Information about the number of lesions radiologically evident
was available in 235 patients: one lesion only was evident in 153
cases (65.1%), multiple lesions were evident in 82 (34.9%).
RESULTS
Surgery
The surgical approach was thoracotomy in 247 patients (75.3%),
sternotomy in 74 (22.5%) and video-assisted thoracoscopy in
seven (2.1%). The types of lung resection performed are listed in
Table 1. An extrapulmonary resection (chest wall, diaphragm,
pleura, lymph nodes, mediastinal structures, liver) was required in
50 patients (15.2%).
On pathological assessment, single metastases were present in
197 patients (60%) and multiple metastases in 131 (40%). Fifty-
two patients had four or more metastases. Of the 153 patients with
a solitary radiological lesion, 128 had only one pathologically
proven metastasis (the accuracy of radiological assessment for
single vs multiple lesions was 84%). Evaluation of the hilar or
mediastinal nodes resulted positive in 26 patients (8%). Complete
resection of all melanoma metastases was performed in 282
patients (86% radical metastasectomy group); 46 patients had a
non-radical metastasectomy (14%). Four patients died in the post-
operative period (1.2%). Adjuvant chemotherapy was used in 107
cases (32.6%), prior to surgery in 47 patients and post surgery in
60. Overall, 300 patients had one metastasectomy operation, 23
had two metastasectomies, and five had three metastasectomies.
Survival
Overall actuarial survival was 18% at 5 years and 14% at 10 years
(median survival 17 months). The overall actuarial survival of
patients in which complete resection was achieved (R0, n = 282)
was 22% at 5 years and 16% at 10 years; no patient with incom-
plete resection (R1–2,  n = 46) was alive at 5 years (median
survival 19 and 11 months respectively, P < 0.01, Figure 1).
In the R0 group, patients with a TPM of > 36 months had a
better long-term survival than patients with a TPM < 36 months
(30% vs 15% at 5 years and 22% vs 11% at 10 years, P < 0.01).
The number of pathologically proven metastases also affected
survival: patients with a single lesion had better survival than
those with multiple lesions (25% vs 19% at 5 years and 22% vs 7%
at 10 years, P = 0.03). Prognosis was significantly poorer with four
or more metastases (8% at 5 years).
No effect on survival was demonstrated for age, sex, surgical
approach, type of lung resection, extrapulmonary resection,
chemotherapy before or after metastasectomy, number of metasta-
sectomies, hilar-or mediastinal-node involvement.
Postponing metastasectomy did not aid the selection of patients
with better prognosis. In fact the 5-year survival of patients oper-
ated within a month of detection (170 patients) was similar to the
survival of those operated upon later (158 patients), 20% vs 26%
respectively (median survival 30 vs 22 months, P = 0.3).
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Table 1 Lung metastasectomies for melanoma: clinical features of the
International Registry Series
R0 R1–2 Total %
Mean age 49 47 49 –
Males 156 25 181 55.2
Delay
<1 month 150 20 170 51.8
>1 month 132 26 158 48.2
Approach
unilateral 224 30 254 77.4
bilateral 58 16 74 22.6
Resection
pneumonectomy 13 1 14 4.3
lobectomy 76 8 84 25.6
sublobar 194 36 230 70.1
TPM (months)
0 12 3 15 4.5
1–11 30 10 40 12.2
12–35 89 13 102 31.1
>36 143 20 163 49.7
(R0 = Radical metastasectomy; R1–2 = non-radical metastasectomy; delay =











Figure 1 Long = term survival according to the radicality of metastasectomy
(16% vs 0% at 10 years, P < 0.01)Pattern of failure
During the follow-up period, 221 patients died (crude mortality
rate 67%), 184 in the R0 group (crude mortality rate 65%) and 37
in the R1–2 group (mortality rate 80%). Mean time from metasta-
sectomy to death was 18 months (19 months for R0 patients and 9
months for R1–2 patients). One hundred and eighty patients
(63.8%) experienced recurrence of melanoma after radical
pulmonary metastasectomy: intrathoracic recurrence in 48 cases,
intra- and extrathoracic in 50 cases and extrathoracic relapse alone
in 82 cases. The most common sites of extrathoracic disease were
brain (58 patients) and liver (15 patients).
Of 48 patients with intrathoracic recurrence, further surgery was
possible in 28 (58.3%). Twenty-three such patients had a second
metastasectomy, five had three metastasectomies. Their long-term
survival was 19% at 5 years.
Prognostic grouping
The three significant prognostic factors from multivariate analysis
(radicality, TPM, number of lesions) were used to design a system
of classification according to the proposal of the International
Registry of Lung Metastases (Pastorino et al, 1997). Following
these guidelines, the 328 patients of the study were divided into
four groups:
• Group I: patients who had radical metastasectomy and no
adverse prognostic factors (TPM > 36 months and single
metastasis, n = 96)
• Group II: radical metastasectomy and one unfavourable factor
(TPM < 36 months or multiple metastases, n = 126)
• Group III: radical metastasectomy and two unfavourable
factors (TPM < 36 months and multiple metastases, n = 52)
• Group IV: incomplete metastasectomy (n = 46).
The survival difference among these groups was highly significant
(log-rank 2 29.6, df 3, Figure 2). Group I survival was 29% at 5
years and 26% at 10 years. Group II survival was 20% at 5 years
and 11% at 10 years. Group III survival was 7% at 5 years. Group
IV had no 5-year survivors.
DISCUSSION
Metastatic melanoma has a very poor prognosis, with a median
survival of about 9 months (Falkson, 1998). For some of these
patients with limited metastatic disease, surgical resection can
offer the best chance of cure (Fletcher, 1998). This was confirmed
even in the subset of pulmonary metastatic melanoma in two large
series previously published (Tafra et al, 1995; Harpole et al, 1992).
However, pulmonary metastasectomy for melanoma has the
lowest long-term survival after surgery compared to germ cell
tumours, carcinomas and sarcomas (Pastorino et al, 1997). This
peculiarity emphasizes the importance of prognostic indicators to
avoid surgery in patients who will not benefit. When the lung is the
only site of recurrence, radicality of pulmonary metastasectomy is
the main factor affecting survival (Harpole et al, 1992; Tafra et al,
1995; Pastorino et al, 1997).
We tested many variables on the IRLM series, which represents
the largest group of patients with surgically treated pulmonary
metastatic melanoma available in the literature, in the search for
independent prognostic predictors after lung metastasectomy. In
particular, the grouping system proposed by the International
Registry of Lung Metastases in 1997 was tested, taking into
account the radicality of resection and two more risk factors:
number of pathologically proven lesions and time elapsed from
primary tumour to pulmonary metastases.
Having a single lesion and a long time to pulmonary metastases
means a better survival in surgically treated patients with
pulmonary metastases from melanoma (Harpole et al, 1992); it
was suggested by Tafra et al (1995) and is confirmed by our study.
Applying the IRLM grouping system, long-term results remain
satisfactory at 10 years when a radical resection is achieved and
only one risk factor is present (Groups I and II). On the contrary,
metastasectomy is not effective when multiple metastases are
associated with a TPM shorter than 3 years.
Given the fact that the proposed grouping system has a good
prognostic value when applied retrospectively, it would seem
logical to use a similar system to select patients with pulmonary
metastases from melanoma for surgery.
Preoperative evaluation of the number of lesions is crucial. In
the Registry experience, the accuracy of radiological assessment in
detection of single lesions was good (84%). CT scan was not
routinely used in the early period of the series but accuracy
remains very similar throughout (considering only the last 10
years, period 1985–1995: accuracy 86%). It is expected that spiral
CT scan and possibly PET will improve the diagnostic power of
radiological assessment (Holder et al, 1998). Applying the IRLM
grouping system prospectively, it can be argued that limiting
surgery for pulmonary metastases to Groups I and II would
produce better results in melanoma patients.
Other factors indicated in the literature as important prog-
nostic indicators were considered in this study. Chemotherapy,
which is reportedly associated with better survival in pulmonary
metastatic melanoma (Harpole et al, 1992), did not influence
survival after surgery in the IRLM series. This conclusion is
greatly limited by the retrospective nature of the IRLM data
because information on inclusion criteria, regimen used and
response rates are missing. Moreover, the role of immuno-
therapy, reported to be effective as a post-surgery adjuvant treat-
ment (Tafra et al, 1995), was not verified by this study for the
same reason.
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Figure 2 Prognostic grouping proposed by the Registry in 1997 confirmed
its value when applied to lung metastases from melanoma. Benefit of
metastasectomy in Group I and II patients is still evident 10 years after
metastasectomyThe importance of nodal spread in metastatic disease cannot be
disregarded. Harpole described a poorer prognosis for node-posi-
tive patients. This point was not confirmed by our study. This
difference could be due to at least two factors: the small number of
node-positive patients in the IRLM series (26 patients) compared
with Harpole’s series (507); all patients with clinical node-posi-
tivity were compared with node-negative cases in Harpole’s series,
regardless of whether they had been resected or not. The IRLM
series considered only resected patients and it is reasonable to
assume that patients with clinical mediastinal node-positivity were
excluded from operation. Moreover, lymphadenectomy is not
routinely performed during lung metastasectomy and therefore
some patients may not be properly staged.
Recently, tumour doubling time (TDT) was indicated as an
important tool for selection of patients with melanoma pulmonary
metastases who are likely to benefit from metastasectomy (Ollila
et al, 1998). For a TDT < 60 days, chemotherapy and biological
therapy are recommended with surgery performed afterwards only
if the TDT has been modified. Unfortunately, no data about TDT
was available from the Registry. TPM and TDT express both the
biological behaviour of the disease before and after clinical detec-
tion of pulmonary metastases. If TDT is shown to have an impact
independent from TPM, it could be tested to identify a subset of
patients with short TPM but long TDT who might still have a
chance of cure after surgery.
In conclusion, despite previously cited limitations, data from the
Registry confirms that surgery plays an important role in carefully
selected cases of pulmonary metastatic melanoma. The grouping
system proposed by the IRLM can help this selection, as Groups I
and II maintain an acceptable survival even 10 years after metasta-
sectomy. However, patients with multiple metastases and a short
TPM have an unfavourable outcome that is not improved by
surgery.
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